申请人:MITSUBISHI KASEI CORPORATION
公开号:EP0236510A1
公开(公告)日:1987-09-16
Novel prostacyclins represented by general formula (I).
wherein R1 represents -CO2R5 or -CONR6R7, A represents (i) -CH=CH-CH2CH2- or (ii) -CH2CH2-O-CH2-, B represents -C=C-, R2 represents alkyl, cycloalkyl, alkenyl, alkynyl, phenyl or phenoxy, R3 represents H, methyl or vinyl, R4 represents H, acyl, tri(C1-7 hydrocarbon)silyl, or a group forming an acetal bond together with the oxygen atom or the hydroxy group, the double bond of the substituent represented by A is E, Z, or a mixture thereof, and the asymmetric center of the substituent represented by R2 is R- or S-conformation, or a mixture thereof and their use as drugs for improving blood circulation or for antithrombotic use, or as antiulcer drugs.
通式(I)代表的新型前列环素。
其中 R1 代表-CO2R5 或-CONR6R7,A 代表(i)-CH=CH-CH2CH2-或(ii)-CH2CH2-O-CH2-,B 代表-C=C-,R2 代表烷基、环烷基、烯基、炔基、苯基或苯氧基,R3 代表 H、甲基或乙烯基,R4 代表 H、酰基、三(C1-7 烃基)硅烷基或与氧原子或羟基一起形成缩醛键的基团、A代表的取代基的双键为E、Z或它们的混合物,R2代表的取代基的不对称中心为R构型或S构型或它们的混合物,以及它们作为改善血液循环或抗血栓形成药物或抗溃疡药物的用途。